What is HC Wainwright’s Forecast for BBIO FY2027 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share estimates for BridgeBio Pharma in a research note issued to investors on Monday, March 9th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $1.83 per share for the year. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share.

A number of other research firms have also issued reports on BBIO. Truist Financial increased their price target on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Leerink Partners upped their price objective on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Finally, JPMorgan Chase & Co. increased their price objective on BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average price target of $83.35.

BridgeBio Pharma Trading Up 13.2%

Shares of NASDAQ BBIO opened at $74.32 on Tuesday. BridgeBio Pharma has a one year low of $28.33 and a one year high of $84.94. The business has a 50-day moving average price of $73.42 and a two-hundred day moving average price of $65.74. The firm has a market capitalization of $14.41 billion, a PE ratio of -19.66 and a beta of 1.13.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. The company’s quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter last year, the company earned ($1.40) EPS.

Insiders Place Their Bets

In other BridgeBio Pharma news, Director Andrea Ellis sold 64,921 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the transaction, the director directly owned 18,589 shares in the company, valued at $1,205,868.43. This trade represents a 77.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 28,053 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $71.39, for a total value of $2,002,703.67. Following the completion of the sale, the chief executive officer directly owned 234,451 shares of the company’s stock, valued at $16,737,456.89. This represents a 10.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 227,095 shares of company stock worth $16,099,240 in the last 90 days. 18.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $25,000. Aster Capital Management DIFC Ltd acquired a new position in BridgeBio Pharma during the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd bought a new position in shares of BridgeBio Pharma in the third quarter valued at approximately $34,000. Jones Financial Companies Lllp bought a new position in shares of BridgeBio Pharma in the first quarter worth about $35,000. Finally, First Horizon Corp acquired a new position in shares of BridgeBio Pharma during the 3rd quarter worth about $36,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: JPMorgan raised its price target to $94 and kept an “overweight” rating, implying meaningful upside from current levels; this large-bank upgrade likely boosted investor demand. JPMorgan raises price target
• Positive Sentiment: William Blair initiated coverage with an “outperform” rating, adding institutional analyst support and fresh buy-side attention. William Blair starts coverage
• Positive Sentiment: HC Wainwright revised estimates aggressively, forecasting FY2027 EPS of $1.83 and maintaining a $100 target — another high-profile bullish projection that supports investor optimism. HC Wainwright estimate
• Positive Sentiment: Media coverage is highlighting BridgeBio’s rare-disease pipeline as a growth catalyst, which can lift sentiment and attract speculative interest in the biotech name. BridgeBio pipeline article
• Neutral Sentiment: Reports flagged a “large increase” in short interest, but the published data shows zero shares/NaN and a days-to-cover of 0.0 — the short-interest figures appear erroneous or incomplete, so they offer no clear directional signal today.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.